Read on Twitter
#RENE
Totally agree $CDAK are around 18months further advanced in the development of Exosomes (delivery vehicle)
#RENE Mcap= £60m
$CDAK MCap= $591m
3 Companies evaluating RENE's platform
Currently snowed under with demand off other companies for Proof of Concept trials https://twitter.com/Stockonomist/status/1347110428095229952
Totally agree $CDAK are around 18months further advanced in the development of Exosomes (delivery vehicle)
#RENE Mcap= £60m
$CDAK MCap= $591m
3 Companies evaluating RENE's platform
Currently snowed under with demand off other companies for Proof of Concept trials https://twitter.com/Stockonomist/status/1347110428095229952
#RENE
One of the brilliant things which Exosomes do is they have the ability to pass through the Blood Brain Barrier delivering signals and regulation into the Brain
This is extremely difficult to do and most drug delivery mechanisms fail to do this
One of the brilliant things which Exosomes do is they have the ability to pass through the Blood Brain Barrier delivering signals and regulation into the Brain
This is extremely difficult to do and most drug delivery mechanisms fail to do this
#RENE
David Sinclair
A Professor in Genetics At Harvard Medical School
Who specialises in the Biology of Ageing explains
3min30sec
As we age “Sirtuins” which protect the body loose their ability to Silence (siRNA) Genes which should not be there
David Sinclair
A Professor in Genetics At Harvard Medical School
Who specialises in the Biology of Ageing explains
3min30sec
As we age “Sirtuins” which protect the body loose their ability to Silence (siRNA) Genes which should not be there
#RENE
He believes this is partly why we have Diseases of the Brain
RENE have stayed in their recent Webinar exceptional demand from Top Cell and Gene Therapy players to partner with their Exosome platform, a platform that had already proven it can package siRNA and mRNA
He believes this is partly why we have Diseases of the BrainRENE have stayed in their recent Webinar exceptional demand from Top Cell and Gene Therapy players to partner with their Exosome platform, a platform that had already proven it can package siRNA and mRNA
#RENE
The question is over the next 12 months HOW MANY Major Global Cell and Gene Therapy players will RENE develop partnerships with?
The question is over the next 12 months HOW MANY Major Global Cell and Gene Therapy players will RENE develop partnerships with?
#RENE
Exosome Collaboration Deals to date include
MAJOR Pharma
MAJOR Biotech
Including research grants from Innovative UK
Demand for their Exosome platform currently OUTSTRIPPING their functional capacity showing this delivery mechanism to potentially be breakthrough
Exosome Collaboration Deals to date include
MAJOR Pharma
MAJOR Biotech
Including research grants from Innovative UK
Demand for their Exosome platform currently OUTSTRIPPING their functional capacity showing this delivery mechanism to potentially be breakthrough
#RENE
Update from the CEO regarding their Phase 2 trial in Retinitis pigmentosa (RP) an Eye Disease that causes blindness
Only Therapeutic currently on the market addresses 2% of the RP population
ReNeurons therapy shown to treat 100% of the population
Update from the CEO regarding their Phase 2 trial in Retinitis pigmentosa (RP) an Eye Disease that causes blindness
Only Therapeutic currently on the market addresses 2% of the RP population
ReNeurons therapy shown to treat 100% of the population
#RENE
Not only has RENE stem cell therapy
prevented continued deterioration
of vision it has
significant improved and restored vision on average by 8-10 letters
Not only has RENE stem cell therapy
prevented continued deterioration
of vision it has
significant improved and restored vision on average by 8-10 letters
#RENE
This is exciting as EYLEA
(One of the best selling drugs in the world)
Was approved on a visual acuity improvement of 9 Letters
In a different Eye Condition
(Wet AMD)
This is exciting as EYLEA
(One of the best selling drugs in the world)
Was approved on a visual acuity improvement of 9 Letters
In a different Eye Condition
(Wet AMD)
#RENE 
ReNeuron aren’t stopping there
They have decided to DOUBLE the dose in a further Extension study to try to increase the efficacy even further
AIM: Letter Improvement increase from 8/10 Letters
15+ Letters and it’s virtually near enough certain for approval 
ReNeuron aren’t stopping there
They have decided to DOUBLE the dose in a further Extension study to try to increase the efficacy even further
AIM: Letter Improvement increase from 8/10 Letters
15+ Letters and it’s virtually near enough certain for approval
#RENE
1st Patient in the increased dose cohort was reviewed by Data Safety Monitoring board
Allowing RENE to proceed to dose a further 2 patients before the next evaluation
This is an encouraging sign that there are no Serious Adverse Events relating to the increased dose
1st Patient in the increased dose cohort was reviewed by Data Safety Monitoring board
Allowing RENE to proceed to dose a further 2 patients before the next evaluation
This is an encouraging sign that there are no Serious Adverse Events relating to the increased dose
#RENE
3/9 Patients have now been dosed and shortly we will receive a thorough Safety update of the expanded cohort which I anticipated to be good
This trial is open label (ReNeuron can see the safety and results as they go along)
3/9 Patients have now been dosed and shortly we will receive a thorough Safety update of the expanded cohort which I anticipated to be good
This trial is open label (ReNeuron can see the safety and results as they go along)
#RENE
Given the recent enthusiasm by both the CEO and the Principal Investigator validates the thesis that the expansion Cohort will be Safe
Potentially showing further improved GAME CHANGING results for this “innovative” Stem Cell Therapy
Given the recent enthusiasm by both the CEO and the Principal Investigator validates the thesis that the expansion Cohort will be Safe
Potentially showing further improved GAME CHANGING results for this “innovative” Stem Cell Therapy
#RENE
Validation of the HUGE promise of Exosomes
Highly educated individual with vast knowledge and experiance within Medical Research
Ex Chief Scientific Officer to $81.6Bn Gilead
Validation of the HUGE promise of Exosomes
Highly educated individual with vast knowledge and experiance within Medical Research
Ex Chief Scientific Officer to $81.6Bn Gilead
#RENE
Are Exosomes actually the key driver in treating disease
Understand the bodies deep mechanisms beyond cell therapy...
Are Exosomes actually the key driver in treating disease
Understand the bodies deep mechanisms beyond cell therapy...
